Literature DB >> 1534911

Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat.

R Dall'Olio1, O Gandolfi, N Montanaro.   

Abstract

The D2 or D1 dopamine receptor blockers (-)-sulpiride or SCH 23390 antagonized, in a dose dependent manner, the hypermotility induced by the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801 (0.25 mg/kg IP). MK-801 induced hyperactivity was not detected when rats were observed on days 7, 14 or 21 of 21 daily injections of MK-801. This lack of hyperactivity was also noted 5 days after the last administration of the repeated treatment with MK-801. The hypermotility induced by the D2 dopamine receptor agonist LY 171555 (0.3 mg/kg IP) was reduced 5 days following repeated treatment (21 days) with MK-801, while no change in the behavioral responses to the selective D1 agonist, SKF 38393, or the mixed D1/D2 agent apomorphine was detected. The results, although suggesting the involvement of dopaminergic pathways in the behavioral effect of MK-801, are conflicting with regard to the underlying mechanisms and to the adaptive changes of dopaminergic system following repeated NMDA receptor blockade.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534911     DOI: 10.1007/bf02245275

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine.

Authors:  M Hiramatsu; A K Cho; T Nabeshima
Journal:  Eur J Pharmacol       Date:  1989-08-03       Impact factor: 4.432

2.  Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders.

Authors:  H L Klawans; D I Margolin
Journal:  Arch Gen Psychiatry       Date:  1975-06

3.  Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy.

Authors:  D S Segal; A J Mandell
Journal:  Pharmacol Biochem Behav       Date:  1974 Mar-Apr       Impact factor: 3.533

4.  The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice.

Authors:  M Carlsson; A Carlsson
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

5.  Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors.

Authors:  T S Rao; H S Kim; J Lehmann; L L Martin; P L Wood
Journal:  Neuropharmacology       Date:  1990-03       Impact factor: 5.250

6.  Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely moving rat in the same way as activation of dopaminergic transmission.

Authors:  W Dimpfel; M Spüler
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems.

Authors:  M Carlsson; A Svensson
Journal:  Pharmacol Biochem Behav       Date:  1990-05       Impact factor: 3.533

8.  Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice.

Authors:  M Carlsson; A Carlsson
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

9.  The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.

Authors:  E H Wong; J A Kemp; T Priestley; A R Knight; G N Woodruff; L L Iversen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

10.  Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice.

Authors:  S Liljequist; K Ossowska; M Grabowska-Andén; N E Andén
Journal:  Eur J Pharmacol       Date:  1991-03-19       Impact factor: 4.432

View more
  8 in total

1.  Involvement of glutamatergic and dopaminergic systems in the reactivity of mice to spatial and non-spatial change.

Authors:  P Roullet; A Mele; M Ammassari-Teule
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

2.  The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra.

Authors:  K Wedzony; A Czyrak; M Maćkowiak; K Fijał
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

3.  Distal Enteral Feeding Helps Blood Sugar Control in Pancreatectomized Patients.

Authors:  Jin-Ming Wu; Ching-Yao Yang; Ting-Chun Kuo; Hong-Shiee Lai; Pin-Yi Chiang; Su-Hua Hsieh; Yu-Wen Tien
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

4.  Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats.

Authors:  A Ouagazzal; A Nieoullon; M Amalric
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D(2/3) dopamine receptor stimulation in rats.

Authors:  Anna-Maria Biondo; Robert L H Clements; David J Hayes; Brendan Eshpeter; Andrew J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  2005-03-03       Impact factor: 4.530

6.  The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function.

Authors:  R Dall'Olio; R Rimondini; O Gandolfi
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

7.  Chronic treatment with MK-801 affects the behavioral response to both D1 and D2 dopamine agonist in the one-trial inhibitory avoidance.

Authors:  A Mele; C Castellano; A Oliverio
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

8.  Sensorimotor gating impairments induced by MK-801 treatment may be reduced by tolerance effect and by familiarization in monkeys.

Authors:  Patricia G Saletti; Rafael S Maior; Etsuro Hori; Hisao Nishijo; Carlos Tomaz
Journal:  Front Pharmacol       Date:  2015-09-22       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.